Department of Biological Sciences, University of Limerick, V94 T9PX Limerick, Ireland.
Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland.
Nutrients. 2022 Oct 20;14(20):4414. doi: 10.3390/nu14204414.
Platelet-activating factor (PAF) is a lipid mediator that interacts with its receptor (PAF-R) to carry out cell signalling. However, under certain conditions the binding of PAF to PAF-R leads to the activation of pro-inflammatory and prothrombotic pathways that have been implicated in the onset and development of atherosclerotic cardiovascular diseases (CVD) and inflammatory diseases. Over the past four decades, research has focused on the identification and development of PAF-R antagonists that target these inflammatory diseases. Research has also shown that dietary factors such as polar lipids, polyphenols, and other nutrient constituents may affect PAF metabolism and PAF-R function through various mechanisms. In this review we focus on the inhibition of PAF-R and how this may contribute to reducing cardiovascular disease risk. We conclude that further development of PAF-R inhibitors and human studies are required to investigate how modulation of the PAF-R may prevent the development of atherosclerotic cardiovascular disease and may lead to the development of novel therapeutics.
血小板激活因子 (PAF) 是一种脂类介质,通过与受体 (PAF-R) 相互作用来进行细胞信号转导。然而,在某些条件下,PAF 与 PAF-R 的结合会导致促炎和促血栓形成途径的激活,这些途径与动脉粥样硬化性心血管疾病 (CVD) 和炎症性疾病的发生和发展有关。在过去的四十年中,研究的重点是鉴定和开发针对这些炎症性疾病的 PAF-R 拮抗剂。研究还表明,膳食因素,如极性脂质、多酚和其他营养成分,可能通过多种机制影响 PAF 代谢和 PAF-R 功能。在这篇综述中,我们重点关注 PAF-R 的抑制作用,以及这如何有助于降低心血管疾病风险。我们的结论是,需要进一步开发 PAF-R 抑制剂和人体研究,以调查 PAF-R 的调节如何预防动脉粥样硬化性心血管疾病的发展,并可能导致新的治疗方法的发展。